RAC Alpha SerineThreonine Protein Kinase Pipeline Review, H2 2019
Summary
According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.
RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 RACalpha serine/threonineprotein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity. It act as key modulator of the AKTmTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3kinase to mediate the effects of various growth factors such as plateletderived growth factor PDGF, epidermal growth factor EGF, insulin and insulinlike growth factor I IGFI.
The report 'RAC Alpha SerineThreonine Protein Kinase Pipeline Review, H2 2019' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Undisclosed which include indications Endometrial Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, NonSmall Cell Lung Cancer, Ovarian Cancer, TripleNegative Breast Cancer TNBC, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Anal Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor GIST, Glioblastoma Multiforme GBM, Lymphoma, Metastatic Hormone Refractory Castration Resistant, AndrogenIndependent Prostate Cancer, Pancreatic Cancer, Peritoneal Cancer, Proteus Syndrome, Sickle Cell Disease, SmallCell Lung Cancer, Thymoma Thymic Epithelial Tumor, Unspecified Rare Disease and Uterine Cancer.
Scope
The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1
The report reviews RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 targeted therapeutics and enlists all their major and minor projects
The report assesses RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope